Ligand-directed covalent labelling of a GPCR with a fluorescent tag in live cells by Stoddart, Leigh A. et al.
ARTICLE
Ligand-directed covalent labelling of a GPCR with
a fluorescent tag in live cells
Leigh A. Stoddart 1,2,5, Nicholas D. Kindon2,3,5, Omolade Otun1,2, Clare R. Harwood 1,2, Foteini Patera4,
Dmitry B. Veprintsev 1,2, Jeanette Woolard1,2, Stephen J. Briddon 1,2, Hester A. Franks 2,4,
Stephen J. Hill 1,2✉ & Barrie Kellam 2,3✉
To study the localisation of G protein-coupled receptors (GPCR) in their native cellular
environment requires their visualisation through fluorescent labelling. To overcome the
requirement for genetic modification of the receptor or the limitations of dissociable fluor-
escent ligands, here we describe rational design of a compound that covalently and selec-
tively labels a GPCR in living cells with a fluorescent moiety. We designed a fluorescent
antagonist, in which the linker incorporated between pharmacophore (ZM241385) and
fluorophore (sulfo-cyanine5) is able to facilitate covalent linking of the fluorophore to the
adenosine A2A receptor. We pharmacologically and biochemically demonstrate irreversible
fluorescent labelling without impeding access to the orthosteric binding site and demonstrate
its use in endogenously expressing systems. This offers a non-invasive and selective
approach to study function and localisation of native GPCRs.
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F luorescent labelling a protein of interest can be achieved inmany different ways and is an absolute prerequisite formany techniques used to probe both their function and
localisation. For GPCRs, this is often achieved through use of
protein tags (e.g., GFP, SNAP-tag), fluorescently labelled anti-
bodies or fluorescent ligands1. Each of these technologies has its
limitations and they are not readily transferrable to endogenously
expressing systems where GPCRs are expressed at low levels.
Gene editing techniques, such as CRISPR/Cas92, have allowed
labelling of proteins3, including GPCRs4,5, at endogenous levels
but the fluorophore used can dramatically alter expression levels6.
An orthogonal approach to protein labelling uses ligand-directed
chemistry where a fluorophore is connected via a highly reactive,
electrophilic linker to a ligand that binds to the protein of interest.
Upon binding of this conjugate, the linker can undergo a sub-
stitution reaction with a nucleophilic amino acid side chain (Lys,
Ser, Thr, Tyr, Cys) close to the binding site, forming a new
covalent bond between the fluorophore and protein7. The reactive
groups used thus far for labelling proteins are bulky and not
readily accommodated within the binding sites of a GPCR or
suffer from slow reactivity8,9.
Here, using the adenosine A2A receptor (A2AR) as a model
system we describe the rational design of a compound (1) that
can covalently fluorescently label the receptor in a ligand directed
manner. Using a combination of pharmacological and biochem-
ical approaches we demonstrate the covalent labelling of the A2AR
with 1 and that labelling does not impede access to the orthosteric
binding site. In addition, we demonstrate its use in labelling the
A2AR in endogenously expressing systems.
Results and discussion
Rational design of ligand-directed probe for the A2AR. To
overcome the reactive group size and reactivity difficulties
described for ligand-directed labelling approaches8,9, we incor-
porated a smaller phenyl ester group as the reactive moiety
between the orthosteric head-group and fluorophore of a fluor-
escent conjugate for the A2AR, with the phenyl ring forming part
of the binding pharmacophore (Fig. 1a). To enhance the chemical
reactivity of the ester, molecular modelling suggested that the
relatively small fluorine atom, the most electronegative element,
could be introduced onto this phenyl ring and was compatible
with binding of the antagonist into the binding site. If required, a
further increase in chemical reactivity was envisaged by incor-
porating more fluorine atoms onto the phenyl ring. Based on
recent fluorescent antagonists10 and the selective A2AR antagonist
ZM24138511 we designed such a ligand, 1 (Fig. 1b, Supplemen-
tary Fig. 1), and used molecular modelling to guide close proxi-
mity of the phenyl ester with a nucleophilic amino acid side chain
to allow transfer of a Cy5 fluorophore to the receptor (Fig. 1c,
Supplementary Fig. 2). The majority of the ligand-receptor poses
revealed a close proximity (4–7Å) of the ε-amino group of
Lys153 and the electrophilic region of the linker and that the
fluorophore was in a predominately solvated state. Within
the surrounding vestibule of the orthosteric binding pocket of the
A2AR there are surprisingly few nucleophilic side chain residues
and the approximate molecular distances between the electro-
philic centre of the phenyl ester and the two nearest nucleophilic
residues; Lys150 and Ser156 were found to be consistently 8–10 Å
from the carbonyl of the phenyl ester.
Pharmacological and biochemical characterisation of 1 in
model cell systems. To test its labelling efficacy in an over-
expression system, we added increasing concentrations of 1 to
membranes prepared from HEK293 cells expressing SNAP-A2AR
labelled with Lumi4-Tb and measured time-resolved fluorescence
resonance energy transfer (TR-FRET) between Lumi4-Tb and the
Cy5 subsequently attached to the receptor by 1 via ligand-
directed covalent labelling. We detected a concentration-
dependent increase in TR-FRET ratio which could be inhibited
by co-incubation with the unlabelled competitive antagonist
ZM241385 (10 µM; Fig. 2a). This was consistent with specific
binding to the A2AR and resulted in an estimated equilibrium
dissociation constant (KD) of 5.5 ± 2.0 nM for 1 (n= 4). As these
measurements were taken after 1 h, to investigate if this was long
enough to reach maximal labelling, TR-FRET measurements were
also taken at 3 h and 5 h. Figure 2b demonstrates that there was
no increase in the TR-FRET signal after 3 h and 5 h with 250 nM
1, whereas with lower concentrations a time-dependent increase
was seen. This is expected, as the association rate of the ligand
(kon) is dependent on the concentration of ligand used, so for
lower concentrations of ligand it will take longer to bind to all
available receptors and subsequently label them. From these data,
in further experiments the minimum labelling conditions were for
2 h with 250 nM 1.
To test the irreversible nature of this binding interaction, we
added an excess of ZM241385 (10 μM) to membranes previously
labelled with 250 nM 1 and observed very little change in the TR-
FRET ratio over the subsequent 3 h (103.2 ± 6.8% vs. 0 time point,
n= 4). This suggested that the fluorophore remained in close
proximity to the Lumi4-Tb labelled receptor and could not be
displaced by ZM241385, indicating either permanent transfer of
the flurophore or very slow dissociation of the ligand from the
receptor (Fig. 2c). In marked contrast, when we undertook a
similar experimental protocol with the competitive orthosteric
fluorescent antagonist CA200645 (Supplementary Fig. 3a), the
TR-FRET ratio returned to baseline within 5 min of addition of
ZM241385 (Fig. 2c, Supplementary Fig. 3b) indicating full
dissociation from the receptor. To confirm covalent labelling of
A2AR by 1, T-RexTM-293 cells expressing a Twin-Strep-SNAP-
A2AR (TS-SNAP-A2AR) construct were treated with 1 prior to
purification, separation by SDS-PAGE and visualisation of
labelled samples by in-gel fluorescence. A strong band corre-
sponding to Cy5 labelled TS-SNAP-A2AR was observed at 73
kDa, the expected molecular weight of a monomer, and a
concomitant weaker band at 130 kDa (Fig. 2d, Supplementary
Fig. 4). Labelling of A2AR with Cy5 was prevented when the cells
were co-incubated with 1 and ZM241385 (1 μM). The presence of
Cy5 fluorescence after purification and denaturation of A2AR
confirms the hypothesis that a covalent bond is present between
receptor and fluorophore.
1 was designed to label the A2AR with Cy5 and then allow
dissociation of the pharmacophore portion of the ligand from the
orthosteric binding site, enabling additional ligands to subse-
quently bind to the receptor. However, it is conceivable that
labelling the receptor with Cy5 close to the entrance of the
binding pocket may act as a structural barrier and prevent access
of additional ligands12. The A2AR is a Gs coupled receptor and its
activation leads to an increase in cAMP and subsequent
transcription of genes under the control of a cAMP response
element (CRE). Therefore, to determine whether the orthosteric
binding site was accessible after Cy5 labelling of the receptor, we
evaluated the ability of the A2A-selective agonist CGS21680 to
stimulate CRE-mediated gene expression in CHO CRE-SPAP
(secreted placental alkaline phosphatase) cells expressing the
A2AR. In naïve cells, increasing concentrations of CGS21680
produced a concentration-dependent increase in SPAP produc-
tion (pEC50= 7.86 ± 0.09, n= 5). When cells were treated
overnight (16 h) with 1 µM 1, conditions which lead to a
significant fluorescent labelling of the A2AR, and washed prior to
addition of the agonist, CGS21680 remained equally potent
compared to untreated cells (Fig. 2e, pEC50= 8.05 ± 0.16, n= 5;
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p= 0.32, unpaired t-test). A small increase in the maximum
response (13.3 ± 5.2% increase in maximal SPAP production vs.
control, Fig. 2e) is unlikely to be biologically significant. These
data demonstrate that following covalent labelling of the receptor
by 1 the antagonist pharmacophore readily dissociates from the
orthosteric receptor binding site. Furthermore, agonist access to
the orthosteric binding site was not impaired by the covalent
attachment of Cy5 to the receptor.
Visualisation of labelling of A2AR by 1 in model cells. We
visualised the Cy5 labelling of SNAP-A2AR by 1 in live HEK293
cells using confocal microscopy. We observed clear membrane
localisation of the Cy5 fluorescence in the continued presence of 1
and a high degree of co-localisation with the AF488 labelled
SNAP-A2AR (Fig. 3a). This fluorescence labelling was prevented
in the presence of ZM241385 (10 μM), demonstrating again that
the ligand needs to bind to the orthosteric binding site of the
A2AR in order to transfer the fluorescent label. After labelling
with 250 nM 1 for 2 h, we observed no change in fluorescence
intensity at the cell surface despite washing cells four times over 1
h (Fig. 3a–c). The addition of a high concentration of ZM241385
(10 μM) after pre-labelling with 1 also had no influence on the
level of Cy5 fluorescence (Fig. 3b, Supplementary Fig. 5). These
data demonstrate that 1 can label A2AR irreversibly with Cy5 in a
live-cell system.
One of the advantages of ligand-directed labelling of proteins
over other labelling methodologies is that selectivity between
closely related proteins can be achieved through the use of a
ligand that binds selectively to the protein of interest. To check
the selectivity of 1 itself, we treated HEK293 cells expressing the
three other adenosine receptor subtypes (SNAP-labelled A1R,
A2BR, A3R) with 1 and determined the levels of labelling with Cy5
using confocal imaging (Fig. 3d). We observed no specific Cy5
fluorescence in cells expressing A1R, A2BR or A3R. This high
degree of selectivity of 1 for A2AR over the other three adenosine
receptor subtypes cannot be attributed solely to the selectivity of
ZM241385 as it is reported to be only 60 fold selective for A2AR
over A2BR11. It is therefore likely that this selectivity also results
from close proximity of nucleophilic residues only present within
A2AR to the reactive core of 1 when it is resident within the
orthosteric binding site of the receptor (Supplementary Fig. 6).
Ligand-directed labelling of endogenously expressed A2AR. As
1 showed selectivity for A2AR over other adenosine receptor
subtypes, we then investigated if it could be used to label endo-
genously expressed A2ARs. For this we selected the human breast
cancer cell line SK-BR-3 and human monocyte-derived macro-
phages which are both known to express the A2AR13–15. Live-cell
confocal imaging of SK-BR-3 cells treated with 1 showed Cy5
labelling, which was prevented by the presence of ZM241385
(Fig. 4a). When compared to the imaging observed in the
HEK293 cells overexpressing SNAP-A2AR (Fig. 3a), the labelling
in the SK-BR-3 cells is more punctate. The SK-BR-3 cells have a
flat morphology when compared HEK293 cells and as thus it is
difficult to obtain a halo of plasma membrane labelling. In
addition, there appears to be more intracellular clusters of
receptors which may be due to labelled A2AR which has been
constitutively trafficked by the vesicular machinery in the cells. In
addition, ZM241385-senstitive labelling of macrophages with
Cy5 was observed via flow cytometry (Fig. 4b, p < 0.0001, two-
sided unpaired T-test with Welch’s correction; Fig. 4c, p= 0.007,
Fig. 1 Schematic and molecular modelling of a ligand designed to covalently label A2AR. a Schematic illustration of ligand-directed labelling of A2AR by 1.
b Chemical structure of 1. c Cross-eyed stereo view of 1 docked into a refined model of the human A2a receptor (PDB: 5K2B) highlighting Lys153 as the
closest nucleophilic amino acid residue (~4.3Å).
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two-sided paired t-test; Supplementary Fig. 7) demonstrating
labelling of endogenous A2AR with 1.
Ligand directed labelling of a GPCR compliments the very
successful traditional labelling approaches such as the SNAP-
tag16 and NanoLuc17 technologies. As an extension of studying
GPCRs with fluorescent ligands, this means that each GPCR
target requires a separate ligand-directed label to be developed18.
With the explosion in the number of high-resolution structures
solved19, the rational design of ligand-directed labels for GPCRs
should be achievable through the use of molecular modelling to
reduce the size of the reactive groups and gain selectivity over
closely related receptor subtypes through careful positioning of
these groups close to subtype-specific nucleophilic residues. An
often-observed pitfall with fluorescent ligands is high levels of
non-specific binding, which can occlude the detection of specific
binding in endogenously expressing systems20. As multiple wash
steps can be performed in a ligand-directed labelling approach,
this has the potential to reduce the levels of non-specific binding
observed. Fluorescent ligands21–23 and the recently described
ligand-directed label for the μ opioid receptor24 have been used to
visualise the organisation and expression pattern of endogenously
expressed receptors. Due to the proposed role of the A2AR in
neurological conditions such as Parkinson’s disease25 and as a
target for cancer immunotherapy26, the approach described here
has the potential to allow the function of the A2AR in normal and
disease conditions to be studied.
In summary, we have described rational design of a compound
that can covalently and selectively label a GPCR with a florescent
molecule without affecting the binding site of the receptor. Ligand
directed labelling of GPCRs is a non-invasive approach to
visualise GPCRs and opens up the possibilities to study ligand
binding, receptor trafficking and signalling in endogenously and
clinically relevant systems.
Methods
Chemicals and solvents of analytical and HPLC grade were purchased from
commercial suppliers and used without further purification. Sulfo-Cyanine5 car-
boxylic acid was purchased from Lumiprobe. Reactions were monitored by thin-
layer chromatography on commercially available silica pre-coated aluminium-
backed plates (Merck Kieselgel 60 F254). Visualisation was under UV light (254 nm
and 366 nm). Flash column chromatography was performed using silica gel 60,
230–400 mesh particle size (Sigma Aldrich). NMR spectra were recorded on a
Bruker-AV 400. 1H NMR spectra were recorded at 400.13 MHz and 13C NMR
spectra at 126.00 MHz. Chemical shifts (δ) are recorded in parts per million (ppm)
and coupling constants are recorded in Hz. The following abbreviations are used to
described signal shapes and multiplicities; singlet (s), doublet (d), triplet (t),
quadruplet (q), broad (br), dd (doublet of doublets), ddd (double doublet of
doublets), dtd (double triplet of doublets) and multiplet (m). Processing of the
NMR data was carried out using the NMR software Topspin. LC-MS spectra were
recorded on a Shimadzu UFLCXR system coupled to an Applied Biosystems
Fig. 2 Pharmacological and biochemical characterisation of 1. a TR-FRET saturation binding curves obtained by treating membranes containing Lumi4-Tb
labelled SNAP-A2AR with increasing concentrations of 1 in the absence (closed circles) or presence (open circles) of 10 µM ZM241385 for 1 h at 37 °C prior
to determination of TR-FRET ratio. Data shown are representative of four experiments and each data point represents mean ± s.e.m of triplicate
determinations. b TR-FRET measurements as detailed in a taken after 1, 3 and 5 h for 4 nM (open circles) and 250 nM (diamonds) 1. Data shown are
specific TR-FRET ratios and represents mean ± SEM of four experiments performed in triplicate. c Membranes containing Lumi4-Tb labelled SNAP-A2AR
were pre-treated with 250 nM 1 (5 h, black circles) or CA200645 (2 h, green squares) at 37 °C prior to measurement of TR-FRET ratio. After basal reads,
10 µM ZM241385 was added and measurements taken every 2min (1) or 5 s (CA200645) for 5 min (CA200645) or 180min (1). Non-specific binding
was determined in the presence of 10 µM ZM241385 and data normalised to total and non-specific binding at the zero time point. Each data point
represents mean ± s.e.m. of four experiments each performed in triplicate. d T-RexTM-293 cells induced to express TS-SNAP-A2AR were treated with 500
nM 1 in the presence or absence of 1 µM ZM241385. Untreated cells were used as a control. TS-SNAP-A2AR was purified and separated on an SDS-PAGE
gel and direct Cy5 fluorescence was visualised using in-gel fluorescence. Gel shown is representative of three independent experiments. e CHO CRE-SPAP
cells were treated with (open squares) or without (closed circles) 1 µM 1 for 16 h. Cells were washed for 30min prior to the addition of increasing
concentrations of CGS21680 and levels of CRE-mediated SPAP production measured after 5 h. Data are normalised to basal (in the absence of agonist and
1) and maximal CGS21680 response in the absence of 1 and each point represents the mean ± s.e.m. of five experiments performed in triplicate.
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-01451-w
4 COMMUNICATIONS BIOLOGY |           (2020) 3:722 | https://doi.org/10.1038/s42003-020-01451-w | www.nature.com/commsbio
API2000 and visualised at 254 nm (channel 1) and 220 nm (channel 2). LC-MS was
carried out using a Phenomenex Gemini-NX C18 110 A, column (50 mm × 2
mm× 3 μm) at a flow rate 0.5 mL/min over a 5 min period. All high resolution
mass spectra (HRMS) were recorded on a Bruker microTOF mass spectrometer
using MS electrospray ionisation operating in positive or negative ion mode. RP-
HPLC was performed on a Waters 515 LC system and monitored using a Waters
996 photodiode array detector at wavelengths between 190 and 800 nm. Spectra
were analysed using Millenium 32 software. Semi-preparative HPLC was per-
formed using YMC-Pack C8 column (150 mm × 10 mm × 5 μm) at a flow rate of
5.0 mL/min using a gradient method of 20–70% B over 15 min (Solvent A= 0.1%
formic acid in H2O, solvent B= 0.1% formic acid in CH3CN). Analytical RP-HPLC
was performed using a YMC-Pack C8 column (150 mm × 4.6 mm × 5 μm) at a flow
rate of 1.0 mL/min. Final products were one single peak and >98% pure. The
retention time of the final product is reported using a gradient method of 10–95%
solvent B in solvent A over 26 min. (Solvent A= 0.1% formic acid in H2O, solvent
B= 0.1% formic acid in CH3CN).
2-(Furan-2-carbonyl)hydrazine-1-carboximidamide (3). 2-Furoic hydrazide (2)
(6.0 g, 47.5 mmol) and 2-methyl-2-thiopseudourea hemisulfate salt (33.1 g, 238
mmol) were added to a stirred solution of sodium hydroxide (3.04 g, 76 mmol) in
water (150 ml) at room temperature. After 24 h, the precipitate was collected by
filtration and washed with water and diethyl ether to give 2-(furan-2-carbonyl)
hydrazine-1-carboximidamide27. Yield 4.00 g (23.8 mmol, 50%) and used directly
in the next step without further purification.
3-(Furan-2-yl)-1H-1,2,4-triazol-5-amine (4). 2-(Furan-2-carbonyl)hydrazine-1-
carboximidamide (3) (4.0 g, 23.8 mmol) was suspended in water (70 mL) and the
mixture heated under reflux for 24 h27. The reddish solution was evaporated to
dryness and the resulting solid slurried in water, collected by filtration and dried to
give 3-(furan-2-yl)-1H-1,2,4-triazol-5-amine27. Yield 2.8 g (18.6 mmol, 78%). 1H
NMR (400MHz, DMSO) δ 12.07 (s, 1H), 7.68 (s, 1H), 6.68 (d, J= 3.3 Hz, 1H), 6.54
(s, 1H), 6.07 (s, 2H).
2-(Furan-2-yl)-5-(methylthio)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine
(5). Dimethyl N-cyanodithioiminocarbonate (2.2 g, 15 mmol) and 3-(furan-2-yl)-
1H-1,2,4-triazol-5-amine (2.2 g, 14.6 mmol) were mixed and heated at 170 °C
under nitrogen for 1 h27. After cooling the crude reaction mixture was dissolved in
methanol and dichloromethane and absorbed on to silica. Purification was by silica
gel chromatography eluting with 5–10% ethyl acetate in dichloromethane to give 2-
(furan-2-yl)-5-(methylthio)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine27. Yield
1.4 g (5.6 mmol, 38%). LC/MS (m/z) 248.9 (M+ 1), r.t. 2.47 min, 1H NMR (400
MHz, DMSO) δ 9.11–8.54 (br s, 2H), 7.93 (dd, J= 1.8, 0.8 Hz, 1H), 7.17 (dd, J=
3.4, 0.8 Hz, 1H), 6.72 (dd, J= 3.4, 1.8 Hz, 1H), 2.52 (s, 3H).
2-(Furan-2-yl)-5-(methylsulfonyl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-
amine (6). 3-chloroperbenzoic acid (3.8 g, 22 mmol) was added portionwise over
3 min to a stirred suspension of 2-(furan-2-yl)-5-(methylthio)-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-7-amine (1 g, 4.0 mmol) in dichloromethane (100 mL)27. Initially a
clear solution formed and then a precipitate. After 16 h, the mixture was con-
centrated to 10 ml and ethanol (10 mL) added. The mixture was concentrated to
10 mL and the product allowed to crystallise out over 3 h which was collected by
filtration to give 2-(furan-2-yl)-5-(methylsulfonyl)-[1,2,4]triazolo[1,5-a][1,3,5]
triazin-7-amine27. Yield 0.9 g (3.2 mmol, 80%). LC/MS (m/z) 281.2 (M+ 1), r.t.
2.12 min, 1H NMR (400MHz, DMSO) δ 9.81 (s, 1H), 9.48 (s, 1H), 7.99 (dd, J=
1.8, 0.8 Hz, 1H), 7.27 (dd, J= 3.4, 0.8 Hz, 1H), 6.76 (dd, J= 3.5, 1.8 Hz, 1H), 3.37
(s, 3H).
2-(Furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino)butyl)carba-
mate (7). tert-Butyl N-(4-aminobutyl)carbamate (0.3 g, 1.6 mmol) in acetonitrile
(1.5 ml) was added to a stirred solution of 2-(furan-2-yl)-5-(methylsulfonyl)-[1,2,4]
triazolo[1,5-a][1,3,5]triazin-7-amine(0.3 g, 1.07 mmol) in acetonitrile (3 ml). After
2 h, the reaction mixture was absorbed onto isolute and applied to a silica gel
column eluting with 5–10% methanol in dichlormethane to give tert-butyl (4-((7-
amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino)butyl)carba-
mate. Yield 0.3 g (0.78 mmol, 73%). 1H NMR (400MHz, DMSO) δ 8.25-7.93 (m,
2H), 7.87 (d, J= 1.8 Hz, 1H), 7.54–7.35 (m, 1H), 7.04 (d, J= 3.6 Hz, 1H), 6.82–6.77
(m, 1H), 6.68 (dd, J= 3.5, 1.9 Hz, 1H), 3.30-3.19 (m, 2H), 2.93 (q, J= 6.5 Hz, 2H),
1.53–1.46 (m, 2H), 1.45–1.39 (m, 2H), 1.37 (s, 9H).
N-(4-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)
amino)butyl)-3-fluoro-4-hydroxybenzamide (8). tert-Butyl (4-((7-amino-2-
(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino)butyl)carbamate (0.035
g, 0.09 mmol) in dichloromethane (5 ml) was treated with trifluoroacetic acid (2
ml). After 35 min the solution was evaporated to dryness. Toluene (10 ml) was
Fig. 3 1 is selective and can be used to visualise A2AR in live cells. a Live HEK293 cells expressing SNAP-A2AR were labelled with SNAP-surface-AF488
and then treated with 250 nM 1 in the absence or presence of ZM241385 for 2 h prior to the capture of single equatorial confocal images. Cells treated with
250 nM 1 were then washed multiple times over 1 h and then imaged. Left hand column represents Cy5 fluorescence, middle column AF488 fluorescence
and right hand column the merged image. Fluorescent intensity values (8-bit greyscale) were determined for Cy5 (b) and AF488 (c) in membrane regions
of interest from the images obtained as described in a and also in cells treated with 10 μM ZM241385 for 1 h after 2 h incubation with 250 nM 1 (images
shown in Supplementary Fig. 4). Each point represents the values obtained from one cell. Images were obtained in four independent experiments, error
bars represent mean ± SD. d HEK293 cells expressing SNAP tagged versions of one of the four adenosine receptor subtypes (A1, A2A, A2B or A3) were
labelled with SNAP-surface-AF488 prior to the addition of 250 nM 1 for 2 h prior to the capture of single equatorial images. Images shown in a and d are
representative of images taken in four (a) or three (d) independent experiments, with all image sets taken using identical settings for laser power, gain, and
offset in both channels. Scale bar shown represents 10 µm.
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added and the mixture evaporated to dryness. This process was repeated 2 more
times to remove residual trifluoracetic acid to give N5-(4-aminobutyl)-2-(furan-2-
yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine trifluoroacetate salt which was
used without further purification.
1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide
hexafluorophosphate (HATU) (0.041 g, 0.1 mmol) was added to a stirred solution
of 3-fluoro-4-hydroxybenzoic acid (0.014 g, 0.09 mmol) and diisopropylethylamine
(0.15 ml) in DMF (1 ml). After 0.5 h, the slurry was added to the N5-(4-
aminobutyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine
trifluoroacetate salt and diisopropylethylamine (0.25 ml) in DMF (1 ml). The
mixture was heated at 90 °C for 2 h. After cooling, the solvent was removed under
high vacuum. Purification was by silica gel chromatography eluting with 5–10%
methanol in dichloromethane to give N-(4-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo
[1,5-a][1,3,5]triazin-5-yl)amino)butyl)-3-fluoro-4-hydroxybenzamide. Yield 0.03 g
(0.07 mmol, 70%) as a white solid. LC/MS (m/z) 427.6 (M+ 1), r.t. 2.31 min, 1H
NMR (400MHz, DMSO) δ 10.42 (s, 1H), 8.30 (t, J= 5.6 Hz, 1H), 8.20-8.00 (br s,
2H), 7.87 (d, J= 1.8 Hz, 1H), 7.63 (dd, J= 12.3, 2.1 Hz, 1H), 7.55 (dd, J= 8.4, 2.1
Hz, 1H), 7.55-7.40 (m, 1H), 7.04 (d, J= 3.5 Hz, 1H), 6.98 (t, J= 8.6 Hz, 1H), 6.68
(dd, J= 3.5, 1.8 Hz, 1H), 3.32-3.20 (m, 4H), 1.59-1.53 (m, 4H). 13C NMR (126
MHz, DMSO) δ 165.19, 161.65, 159.68, 156.27, 150.81 (d, J 240 Hz) 150.44, 148.09
(d, J 11.4 Hz), 146.70, 145.08, 126.39 (d, J 5.4 Hz), 124.60 (d, J 2.52 Hz), 117.55





3H-indol-1-ium-5-sulfonate (1). 2-Bromo-1-ethyl-pyridinium tetrafluoroborate
(BEP reagent)(0.32 mg, 1.17 × 10−6 mol) and diisopropylethylamine (10 mg, 7.75 ×
10−5 mol) in dry N,N-dimethylformamide (0.6 ml) was added to sulfo-cyanine-C5
carboxylic acid (1 mg, 1.47 × 10−6 mol). After 15 min in the dark, this solution was
added to N-(4-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)
amino)butyl)-3-fluoro-4-hydroxybenzamide (8) (0.7 mg, 1.6 × 10−6 mol). After 16
h in the dark, the solution was evaporated to dryness under high vacuum.
Purification was by semi-preparative RP-HPLC. The product containing fractions
were combined and concentrated to remove most of the acetonitrile then lyophi-
lised to give 2-((1E,3E)-5-((E)-1-(6-(4-((4-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo
[1,5-a][1,3,5]triazin-5-yl)amino)butyl)carbamoyl)-2-fluorophenoxy)-6-oxohexyl)-
3,3-dimethyl-5-sulfoindolin-2-ylidene)penta-1,3-dien-1-yl)-1,3,3-trimethyl-3H-
indol-1-ium-5-sulfonate as a blue solid. Yield 1.0 mg (9.5 × 10-7 mol, 65%). HMRS
(m/z) M-H calculated for C51H55FN10O10S2: 1049.3455, found M-H: 1049.3452.
Analytical RP-HPLC, retention time 13.80 min.
Molecular docking general method. The refined three-dimensional model of the
human A2a receptor (pdb code: 5K2B) was obtained from the GPCRdb (https://
www.gpcrdb.org) and loaded into SeeSAR docking software (SeeSAR version 10.1;
BioSolveIT GmbH, Sankt Augustin, Germany, 2020, www.biosolveit.de/SeeSAR).
Prior to docking, the binding site was established using the bound ligand
ZM241385 and waters were excluded. Compound 1 was drawn in ChemDraw
Professional 19.1 (Perkin Elmer Informatics Inc.) and imported into SeeSAR via a.
mol file. FlexX docking of 1 was undertaken using ZM241385 as a template, with
the 10 best scoring poses returned using the HYDE scoring function and visually
inspected. Outputs were exported and visualised using PyMOL (Version 1.8
Schrödinger, LLC).
cDNA constructs. We generated SNAP-labelled adenosine receptor constructs by
amplifying the full length sequence of SNAP-tag (New England Biolabs, Ipswich,
MA) and fusing it in frame with the membrane signal sequence of the 5HT3A
receptor with pcDNA3.1 to yield sig.SNAP. We then fused the full-length human
sequence of each of the four adenosine receptor subtypes (with the methionine
start signal removed) to the 3’ end of the sig.SNAP in pcDNA3.1. This gave the
constructs designated as SNAP-A1R, SNAP-A2AR, SNAP-A2BR and SNAP-A3R, all
of which contain the signal sequence. We generated the pcDNA4TO-TS-SNAP-
A2A construct by amplifying the A2A receptor (with the methionine start signal
removed) and inserting into a pcDNA4TO vector (ThermFisher Scientific, Paisley,
UK) containing a Twin-Step-tag® sequence and the SNAP sequence using Gibson
Fig. 4 Labelling of endogenously expressed A2AR by 1. a SK-BR-3 cells were labelled with 250 nM 1 in the (ii) presence or (i) absence of 10 µM
ZM241385 for 2 h prior to the capture of single equatorial confocal images. Images shown are representative of images taken in three independent
experiments, with all image sets taken using identical settings for laser power, gain, and offset in both channels. Scale bar shown represents 10 µm.
b Representative flow cytometry histograph of human macrophages treated with 500 nM 1 (black line) or 500 nM 1 plus 10 μM ZM241385 (red line) for
2 h at 37 °C. c Median fluorescence intensity of macrophages derived from four healthy donors treated as in b (p= 0.007, paired t-test). Each symbol
represents one donor and line shows mean with s.e.m.
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assembly28. This gave the construct designated as TS-SNAP-A2AR. Plasmids will be
made available to other researchers on request to the corresponding authors.
Ligands. CA200645 was from HelloBio (Bristol, UK). ZM 241385 and CGS21680
were from Tocris (Bristol, UK).
Cell culture and transient transfection. Human embryonic kidney 293 (HEK293)
cells expressing the GloSensor cAMP biosensor (HEKG) were obtained from
Promega (Southampton, UK) and were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% foetal calf serum (FCS) and L-glutamine. T-
RExTM-293 cells (Invitrogen) stably expressing the pcDNA4TO TwinStrepSNAP-
A2A (TS-SNAP-A2A) construct were maintained in high glucose DMEM containing
10% FCS, 5 μg/μL blasticidin and 20 μg/μL zeocin. Chinese hamster ovary (CHO)
cells stably expressing a cAMP response element-secreted placental alkaline
phosphatase (CRE-SPAP) reporter were maintained in Dulbecco’s Modified Eagle
Medium:Nutrient Mixture F-12 (DMEM/F12) medium containing 10% FCS and
2mM L-glutamine. SK-BR-3 cells obtained from ATCC (Manassas, VA) were
maintained in McCoy’s 5a Medium supplemented with 10% FCS. All cell lines were
maintained at 37 °C in a humidified atmosphere of air/CO2 (19:1). For transient
transfections, HEK293G cells grown in 8-well chamber slides were transfected with
the required SNAP-adenosine receptor construct using Fugene (Promega)
according to the manufacturers’ instructions 24 h prior to experiment. For SNAP-
A2AAR stable cell line, HEK293G cells were transfected with the SNAP-A2AAR
construct using Fugene and cells expressing the construct were selected by the
addition of 1 mg/mL−1 G418 to the normal growth media for 2–3 weeks. For
A2AAR CRE-SPAP stable cell line, CHO CRE-SPAP cells were transfect with un-
tagged A2AAR (Missouri S&T cDNA Resource Centre, MO, USA) using Lipo-
fectamine (Life Technologies, Paisley, UK) according to the manufacturers’
instructions. Cells expressing A2AAR were selected by the addition of 1 mg/ml−1
G418 to normal growth media for 2–3 week and then dilution-cloned to obtain cell
lines originating from a single cell.
Human macrophage generation. Heparinised whole blood was obtained by
venepuncture from the antecubital fossa of the arm of healthy volunteers after
written informed consent (Ethics from University of Nottingham Ethics commit-
tee, ref 161–1711). Peripheral blood mononuclear cells (PBMC) were immediately
separated by density centrifugation over Ficoll Histopaque 1077 (Sigma) followed
by washes in endotoxin-free phosphate-buffered saline (PBS, Sigma). PBMC were
washed in MACS buffer (PBS+ 1% foetal calf serum (FCS, Sigma)+ 2 µM EDTA
(Sigma)) then incubated with CD14 microbeads (Miltenyi Biotech) and monocytes
isolated by magnetic separation (purity routinely >95%). Purified CD14+mono-
cytes were differentiated into macrophages at 37 °C/5%CO2 for 7 days at 1 × 106/
well in low-attachment 24-well plates (Corning Costar) in macrophage medium
(RPMI 1640 (Sigma) supplemented with 10% FCS and 1% sodium pyruvate
(Sigma)) and 20U/mL recombinant human granulocyte-macrophage colony-sti-
mulating factor (Peprotech) with medium plus additives supplemented at day 4.
Macrophage 1 labelling and flow cytometry. Medium was aspirated from day 7
macrophages and 500 nM 1 in the presence or absence of 10 µM ZM241385 added
in fresh macrophage medium whilst cells remained in the differentiation plate.
Cells were incubated for 2 h at 37 °C/5% CO2 then medium aspirated, wells washed
with cold PBS and macrophages harvested by incubating on ice in cold PBS for
25 min. Cy5 fluorescence was measured by flow cytometry (MacsQuant, Miltenyi
Biotech) and analysed using FlowJo software. Gating strategy is demonstrated in
Supplementary Fig. 7.
Lumi4-Tb labelling and membrane preparation. SNAP-A2A HEKG cells were
grown to confluence in poly-D-lysine coated T175 flasks. Cells were washed once
in PBS, 100 nM SNAP-Lumi4-Tb in 1× Lab Med (CisBio, Bagnols-sur-Ce’ze,
France) was added and incubated for 1 h at 37 °C. After 1 h, SNAP-Lumi4-Tb
solution was removed and replaced with ice-cold PBS, and the cells were removed
from the flask using a cell scraper. The cells were then transferred to a 50 mL tube
and centrifuged at 250 × g for 10 min. The supernatant was discarded and the
resulting pellets were stored at −80 °C. For membrane preparation, cell pellets were
thawed and resuspended in ice-cold PBS and homogenised using an IKA T10
Ultra-Turrax disperser in 10 × 5 s bursts at 15,000 rpm. After removal of unbroken
cells and nuclei by centrifugation at 1200 × g for 10 min, the resulting supernatant
was centrifuged at 41,415 × g for 30 min to obtain the membrane pellet. The pellet
was then resuspended in ice-cold PBS and homogenised by 20 passes at 1000 rpm
using a Kartell serrated pestle and a borsilicate glass homogeniser mortar fitted to
an IKA RW16 overhead stirrer. Protein concentration of the resuspended mem-
branes was determined using a bicinchoninic acid protein assay and SNAP-Lumi4-
Tb membranes stored at −80 °C until required.
TR-FRET binding assay. All TR-FRET assays were performed in opaque bottomed
96-well plates and read on a PHERAstar FS (BMG Labtech, Offenberg, Germany)
with the terbium (donor) excited with 30 flashes of laser at 337 nm and emission
collected at 620 nm (terbium) and 665 nm (Cy5/BY630) 400 ms after excitation.
The TR-FRET ratio was calculated by dividing the Cy5/BY630 emission (665 nM)
by the terbium emission (620 nm). For membrane saturation TR-FRET binding
assays, 2.5 μg of Lumi4-Tb labelled SNAP-A2A membranes were incubated with
the required compounds in HEPES buffered saline solution (HBSS: 145 mmol/L
NaCl, 5 mmol/L KCl, 1.7 mmol/L CaCl2, 1 mmol/L MgSO4, 10 mmol/L HEPES,
2 mmol/L sodium pyruvate, 1.5 mmol/L NaHCO3, 10 mmol/L D-glucose, pH 7.4)
containing 1 mg/ml saponin for 1 h at 37 °C before reading on the PHERAstar. For
dissociation experiments, 2.5 μg of SNAP-A2AR membranes were incubated with
compounds in HBSS plus saponin for 5 h for 1 and 2 h for CA200645 at 37 °C in
96-well plates. After required incubation time, basal TR-FRET readings were taken
on the PHERAstar, for 1-treated membranes 10 μM ZM241385 was added to each
well manually in a 1:1 dilution to ensure adequate mixing and TR-FRET readings
were then taken every 5 min for 3 h as detailed above. For CA200645, 10 µM
ZM241385 was added using the inbuilt PHERAstar injectors. Due to the rapid
dissociation of CA200645, readings were taken every 5 s for 5 min with 20 flashes
per read.
Labelling of cells with 1 for purification and in gel fluorescence. TS-SNAP-A2A
TREx-293 cells were grown to 70% confluence prior to induction of TS-SNAP-A2A
expression by the addition of 1 μg/mL tetracyclin to normal growth medium. After
50 h induction, medium was replaced and to the required flasks 500 nM 1 or 500
nM 1 plus 1 µM ZM241385 added and cells incubated for a further 5 h at 37 °C/5%
CO2. After 5 h, medium was removed and cells washed twice with phosphate
buffered saline (PBS). Cells were then detached from flasks using cell dissociation
solution non-enzymatic (Sigma), washed off with PBS and solutions removed from
the flasks. Cell suspensions were spun at 362 × g for 10 min. Supernatant was
aspirated and cell pellets frozen at −80 °C until use.
Solubilisation and purification of 1 labelled TS-SNAP-A2A. Cell pellets were
thawed on ice, weighed and resuspended in solubilisation buffer (1% n-Dodecyl
β-D-maltoside (DDM) (w/v), 20 mM HEPES, 10% (v/v) glycerol, 150 mM NaCl,
pH 7.5) at a ratio of 1:10 (w/v) of cell pellet to solubilisation buffer. Pellets were
solubilised for 1 h on a DigiRoll 6 roller (SLS, UK) at 80RPM and 4 °C. Samples
were clarified by centrifugation at 4122 × g for 20 min at 4 °C. Purification of TS-
SNAP-A2A was achieved by the use of MagStrep “type3” XT magnetic beads (IBA,
Göttingen, Germany). Beads were prepared by removal of supernatant using a
magnetic separator (IBA, Göttingen, Germany) and then they were washed twice in
solubilisation buffer before being added to samples. Samples were incubated with
beads overnight on a DigiRoll 6 roller set to 80 RPM at 4 °C. The following
morning supernatant was removed from beads using the magnetic separator and
beads were washed twice with wash buffer (0.1% DDM (w/v), 10% glycerol (v/v),
150 mM NaCl, pH 7.5), before resuspension in 30 μL elution buffer (1:9 solution of
10x buffer BXT (IBA) and wash buffer). Elution took place for 5 h on a DigiRoll
6 roller set to 80 RPM at 4 °C. Samples were then separated from beads using
magnetic separator and then immediately processed for electrophoresis.
Gel electrophoresis and in gel fluorescence. Fifteen microlitre of samples con-
taining purified TS-SNAP-A2A were mixed with 5 μL NuPAGETM LDS sample
buffer and resolved on a NuPageTM 4–12% Bis-Tris 15 × 1.0 mm well gel using
NuPageTM MOPs SDS running buffer. Gels were run for 50 min at 200 V. Samples
were not boiled prior to gel electrophoresis. 5 μL PageRulerTM Prestained Protein
Ladder was used as the ladder. Gels were scanned on an Amersham Typhoon
imaging system (GE Healthcare Life Sciences, Pittsburgh, PA) using Fluorstage and
Cy5 670BP30 filter sets with PMT set to auto and pixel size to 200 μm. After
fluorescence was measured, gels were stained with InstantBlue® protein stain
(Expedeon, Cambridge, UK) overnight. Gels were washed twice with dH2O for
5 min before visualising using a standard smart phone camera.
CRE-SPAP gene transcription. A2AR CRE-SPAP cells were grown to confluence
in clear 96-well plates and on the day prior to analysis normal growth medium was
removed and replaced with serum-free medium (SFM; DMEM/F12 supplemented
with 2 mM L-glutamine) with or without 1 μM 1. On the day of the experiment, all
media was removed from wells and fresh SFM media added. Cells were incubated
for 30 min at 37 °C, and then for the 1 overnight treated wells, SFM was removed
and replaced with fresh SFM. Then increasing concentrations of CGS21680 was
added to the required well and plates incubated for 5 h at 37 °C, 5% CO2. After the
5 h incubation, all medium was removed from the cells and replaced with 40 μl of
SFM and incubated for a further 1 h at 37 °C. The plates were then incubated at 65 °
C for 30 min to destroy the endgoneous alkaline phosphatases. After cooling the
plates to room temperature, 5 mM 4-nitrophenyl phosphate in a diethanolamine-
containing buffer (10% (v/v) diethanolamine, 280 mM NaCl, 500 μM MgCl2, pH
9.85) was added to each well. Plates were incubated for 15 min at 37 °C and then
the absorbance at 405 nm was measured using a Dynex MRX plate reader
(Chelmsford, MA, USA).
Confocal microscopy. All confocal microscopy was performed on cells grown on
8-well Labtek chambered coverglasses (Nunc Nalgene). Where appropriate, cells
were labelled with 100 nM SNAP-surface Alexa Fluor 488 (SNAP-AF488; New
England Biolabs) for 30 min at 37 °C/5% CO2 in normal growth media. Cells were
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washed twice in media prior to the addition of the required compounds (250 nM 1
or 250 nM 1+ 10 μM ZM241385) in normal growth media and incubated for 2 h at
37 °C/5%CO2 and then imaged. Where required 10 μM ZM241385 was added after
2 h and cells incubated for a further 1 h prior to imaging. For wash experiments,
cells were imaged after 2 h and then washed every 15 min for 1 h in normal growth
media prior to imaging again. SK-BR3 cells were incubated with or without 10 μM
ZM241385 in normal growth media for 30 min prior to the addition of 250 nM 1
and incubated for 2 h at 37 °C/5% prior to imaging. All imaging was performed
using a Zeiss LSM880 confocal microscope (Carl Zeiss GmbH, Jena, Germany)
using a ×63 plan-Apochromat NA 1.4 Ph3 oil-immersion objective and a 488/561/
633 main dichoroic. For SNAP-AF488 a 488 nm argon laser was used to excite the
fluorophore and the emission was detected between 493 and 628 nm. Cy5 was
excited using a 633 nm HeNe laser and emission collected between 638 and 747 nm
for HEKG cells and between 633 and 695 nm for SK-BR-3 cells. Due to the lower
level of expression in the SK-BR3 cells, a pixel dwell time of 4.12 μs was used,
whereas a pixel dwell time of 2.06 μs was used with HEKG cells. Within each
experiment, a pinhole diameter of 1 Airy unit was used and the laser power, gain
and offset kept constant for each experiment set. To obtain membrane intensity
values, regions of interest were drawn by hand around the cell membranes in Zen
Black image analysis software.
Data analysis. We simultaneously fit the total and nonspecific saturation binding
curves using Eq. 1:
TR  FRET ratio ¼ Bmax: B½ 
B½  þ KD
þ M:½Bð Þ þ Cð Þ ð1Þ
where Bmax is the maximal signal, [B] is the concentration of flurescent ligand in
nM, KD is the equilibrium dissociation constant in nM, M is the slope of the non-
specific binding component and C is the intercept with the y-axis.
The CRE-SPAP data were fit to Eq. 2:
Response ¼ Emax: A½ 
A½  þ EC50
ð2Þ
where Emax is the maximal response, [A] is the concentration of agonist and the
EC50 is the molar concentration of agonist required to generate 50% of the Emax
Statistics and reproducibility. The number of replicates for each experiment is
given in the respective figure legend and was always greater than three. A replicate
was defined as an assay performed on a separate day with a different passage of
cells, transfection or donor.
We carried out statistical analysis using two-tailed paired or unpaired t test as
required.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The authors declare that all reported data in the main and supplementary files will be
provided to other investigators as requested from the corresponding authors. Source data
underlying all figures are provided in Supplementary Data 1. Raw image files, original gel
images and source data for all figures can also be found on Mendeley Data29 (https://doi.
org/10.17632/8p56bzyg8z). The structure of 1 in Fig. 1b is provided in Supplementary
Data 2. The reaction scheme in Supplementary Information is provided in
Supplementary Data 3.
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